MOA

POLIVY: a first-in-class CD79b-targeting antibody-drug conjugate¹

POLIVY delivers a potent cytotoxic agent directly to B cells¹

• POLIVY binds to CD79b, a component of the B-cell receptor, which is only expressed on B cells and in most non-Hodgkin lymphomas^1–3
  
• Binding to CD79b triggers internalisation. The stable VC linker within POLIVY is cleaved, releasing monomethyl auristatin E (MMAE) to bind to microtubules^1–3
  
• MMAE inhibits microtubule polymerisation, disrupts cell division and triggers apoptosis⁴
  

See the phase II efficacy results for POLIVY

Where could POLIVY be used in the treatment pathway?

MOA, mode of action; VC, valine-citrulline; MMAE, monomethyl auristatin E.

References:

1. Dornan D et al. Blood 2009;114(13):2721–2729.
2. Polson AG et al. Blood 2007;110(2):616–623.
3. Palanca-Wessels MC et al. Lancet Oncol 2015;16(6):704–715.
4. Francisco JA et al. Blood 2003;102(4):1458–1465.

M-GB-00002509
Date of preparation: January 2021

▸ Back to top